The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.

The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.

P-glycoprotein (Pgp) extrudes a large variety of chemotherapeutic drugs from the cells, causing multidrug resistance (MDR). The UIC2 monoclonal antibody recognizes human Pgp and inhibits its drug transport activity. However, this inhibition is partial, since UIC2 binds only to 10-40% of cell surface...

Full description

Bibliographic Details
Main Authors: Gábor Szalóki, Zoárd T Krasznai, Ágnes Tóth, Laura Vízkeleti, Attila G Szöllősi, György Trencsényi, Imre Lajtos, István Juhász, Zoltán Krasznai, Teréz Márián, Margit Balázs, Gábor Szabó, Katalin Goda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0107875

Internet

https://doi.org/10.1371/journal.pone.0107875

Similar Items